- Home
- TCBI vs CRSP Comparison
TCBI vs CRSP Comparison
Compare TCBI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBI
- CRSP
- Stock Information
- Founded
- TCBI 1996
- CRSP 2013
- Country
- TCBI United States
- CRSP Switzerland
- Employees
- TCBI N/A
- CRSP N/A
- Industry
- TCBI Major Banks
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCBI Finance
- CRSP Health Care
- Exchange
- TCBI Nasdaq
- CRSP Nasdaq
- Market Cap
- TCBI 2.9B
- CRSP 3.3B
- IPO Year
- TCBI N/A
- CRSP 2016
- Fundamental
- Price
- TCBI $70.26
- CRSP $37.20
- Analyst Decision
- TCBI Hold
- CRSP Buy
- Analyst Count
- TCBI 15
- CRSP 16
- Target Price
- TCBI $76.67
- CRSP $73.07
- AVG Volume (30 Days)
- TCBI 368.3K
- CRSP 2.1M
- Earning Date
- TCBI 07-17-2025
- CRSP 05-06-2025
- Dividend Yield
- TCBI N/A
- CRSP N/A
- EPS Growth
- TCBI N/A
- CRSP N/A
- EPS
- TCBI 1.74
- CRSP N/A
- Revenue
- TCBI $891,496,000.00
- CRSP $37,675,000.00
- Revenue This Year
- TCBI $44.80
- CRSP $26.79
- Revenue Next Year
- TCBI $9.26
- CRSP $297.32
- P/E Ratio
- TCBI $41.30
- CRSP N/A
- Revenue Growth
- TCBI N/A
- CRSP N/A
- 52 Week Low
- TCBI $56.24
- CRSP $30.04
- 52 Week High
- TCBI $91.80
- CRSP $67.88
- Technical
- Relative Strength Index (RSI)
- TCBI 43.88
- CRSP 49.72
- Support Level
- TCBI $70.00
- CRSP $35.38
- Resistance Level
- TCBI $73.60
- CRSP $38.13
- Average True Range (ATR)
- TCBI 1.76
- CRSP 1.73
- MACD
- TCBI -0.51
- CRSP -0.01
- Stochastic Oscillator
- TCBI 3.11
- CRSP 43.06
About TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.